


REMARKS

The purpose of this Preliminary Amendment is to eliminate multiple dependent claims in order to avoid the additional fee. Applicants reserve the right to reintroduce claims to canceled combined subject matter.

Attached hereto is a marked-up version of the changes made to the claims by the current amendment. The attached pages are captioned "**Version With Markings to Show Changes Made**".

Respectfully submitted,



Harry B. Shubin, Reg. No. 32,004
Attorney for Applicants
MILLEN, WHITE, ZELANO & BRANIGAN, P.C.
Arlington Courthouse Plaza 1
2200 Clarendon Boulevard, Suite 1400
Arlington, VA 22201
Direct Dial: 703-812-5306
Facsimile: 703-243-6410
Email: shubin@mwzb.com

AJZ(HBS):jmm

FILED: 17 SEPTEMBER 2001

VERSION WITH MARKINGS TO SHOW CHANGES MADE

Claims 3, 6-7, 9, 12-14, 16-23 have been amended as follows:

3. (Amended) A polypeptide of claim 1 ~~or 2~~ having six cysteine molecules capable of forming -S-S- bridges.
6. (Amended) An isolated polynucleotide encoding a polypeptide of ~~claims 1-5-~~claim 1.
7. (Amended) An isolated polynucleotide comprising a DNA sequence of SEQ. ID. NO. 2,
2, or a DNA sequence complementary to said DNA sequence wherein said polynucleotide is encoding a polypeptide of claim 1-5.
9. (Amended) An expression vector comprising a DNA sequence of ~~claims 6-8-~~claim 6.
12. (Amended) A process for producing a polypeptide of ~~claims 1-5-~~claim 1 comprising a host ~~of claim 10~~which includes an expression vector with an isolated polynucleotide comprising a DNA sequence of SEQ. ID. NO. 2 culturing said host under conditions sufficient for the production of said polypeptide and recovering the polypeptide from the culture supernatant or cell residue.
13. (Amended) An antibody immunospecific for a polypeptide of claims 1-5.
14. (Amended) A pharmaceutical formulation which comprises a polypeptide according to ~~claims 1-5-~~claim 1 and a pharmaceutical acceptable carrier or excipient therefore.
16. (Amended) A pharmaceutical formulation of claims 14 ~~or 15~~ comprising additional drugs wherein the additional drug is selected from aspirin, heparin or streptokinase or a combination thereof.

17. (Amended) Use of a polypeptide according to ~~claims 1-5~~claim 1 for the manufacture of a medicament for the treatment of thromboembolic diseases.
18. (Amended) Use of a polypeptide according to ~~claims 1-5~~claim 1 for coating artificial surfaces.
19. (Amended) Use of a polypeptide according to ~~claims 1-5~~claim 1 for modifying intraocular lenses in order to lessen the thrombogenicity of the lens material.
20. (Amended) Use of a polypeptide according to ~~claims 1-5~~claim 1 for contacting the lens surface
21. (Amended) Use of a polypeptide according to ~~claims 1-5~~claim 1 for covalent crosslinking to modify said lens material.
22. (Amended) Use of antibodies according to claim 13 and a polypeptide according to claim 1-5 isolated from *H. medicinalis* having a molecular weight of about 12 000 \pm 1kD with the biological activity of an inhibitor of collagen-dependent platelet adhesion to measure samples derived from a process for producing a polypeptide comprising a claim 12 host which includes an expression vector with an isolated polynucleotide comprising a DNA sequence of SEQ. ID. NO. 2 culturing said host under conditions sufficient for the production of said polypeptide and recovering the polypeptide from the culture supernatant or cell residue or a treated subject.
23. (Amended) A method for identifying compounds which inhibit (antagonize) or agonize the polypeptide of claim 1-5 by observing the binding, or stimulation or inhibition of a functional response.

FOI 2009-09660